This study will not be proceeding due to lack of funding from anticipated sources

The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.

This is a stratified study for patients with recurrent intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation presenting radiographic progression or recurrence of tumour. Patients are stratified by extent of resection, time to re-irradiation and re-irradiation volume.

Inclusion Criteria:

• histologically-proven intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation
• radiographic evidence of tumour progression or recurrence
• 18 years or older
• ECOG 0 - 2
• signed informed consent form

Exclusion Criteria:

• tumour progression or recurrence within 3 months of initial concurrent chemoradiation
• 6 or more cycles of TMZ administered following chemoradiation at initial diagnosis
• more than one prior course of salvage chemo for recurrent disease
• prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for greater or equal to 3 years
• prior head or neck RT except for T1 glottic cancer